Phagenesis

Phagenyx therapy helps patients regain swallowing function after post-stroke dysphagia.

Phagenyx’s clinical data includes randomized trials and real-world evidence showing improved swallowing safety and patient outcomes.

Phagenyx supports healthcare professionals with treatment guidance, clinical resources, and patient selection tools for post-stroke dysphagia care.

Phagenyx is the first clinically validated neuromodulation system using PES to restore swallowing control in post-stroke dysphagia.

The University of Manchester and Salford Royal Hospital are recruiting patients with idiopathic Parkinson’s disease and swallowing impairment for a study on neurorehabilitation techniques.

Phagenesis treated severe neurogenic post-extubation dysphagia in a COVID-19 patient using pharyngeal electrical stimulation (PES) with the Phagenyx System.

Post-extubation dysphagia affects 44–56% of patients and increases risks of aspiration pneumonia, malnutrition, and longer hospital stays.

The German Society for Neurology recommends pharyngeal electrical stimulation (PES) for dysphagia in tracheotomized patients.

Phagenesis received FDA De Novo approval for the Phagenyx Neurostimulation System, the first therapy using pharyngeal electrical stimulation to restore swallowing function.

Phagenesis offers career opportunities in dysphagia care innovation.

Phagenesis provides support for clinicians, patients, and families through inquiries, media, and partnerships.

Phagenyx demonstrates its use in transforming post-stroke dysphagia care through facility-specific solutions.

Retrain the brain. Restore swallowing control. Phagenyx accelerates swallowing recovery from post-stroke dysphagia.

The **American Heart Association/American Stroke Association (AHA/ASA) 2026 guideline** now includes **pharyngeal electrical stimulation (PES)** as a recognized therapy for stroke rehabilitation. Phagenesis, a company specializing in swallowing function restoration, gains broader clinical validation for its technology in post-stroke recovery programs.

Sep 2026PhagenesisNews article

Phagenesis names Chad Hoskins as CEO following the completion of a $42 million Series D funding round. Hoskins joins the company with extensive experience scaling MedTech therapies and commercializing treatments in the US. Phagenesis specializes in a neurostimulation system designed to address swallowing dysfunction.

Sep 2024PR NewswireNews article

Phagenesis secures £33 million in Series D funding to accelerate expansion in the US and Europe. The company focuses on medical devices for treating swallowing disorders. Investors back its growth plans amid rising demand for specialized therapies.

Mar 2024BusinessCloudNews article

Phagenesis secures a $42 million Series D round led by EQT Life Sciences to advance its neurostimulation system for treating swallowing dysfunction. The medtech company’s technology targets patients with swallowing disorders, offering a non-invasive treatment alternative. The funding supports further development and potential clinical expansion of its core product.

Mar 2024Tech.euNews article